Results of Phase 2 study of lonafarnib in HDV infected patients published
20 July 2015 | By Victoria White
Results of the first Phase 2a study of lonafarnib in patients with chronic hepatitis delta virus (HDV) infection have been published...
List view / Grid view
News
CheckMate -025, a Phase III Opdivo renal cell cancer trial, stopped early
20 July 2015 | By Victoria White
The CheckMate -025 study evaluating Opdivo versus everolimus in patients with advanced or metastatic RCC has been stopped early as it met its endpoint...
FDA orphan drug designation for C2N-8E12 for the treatment of progressive supranuclear palsy
20 July 2015 | By Victoria White
The US FDA has granted C2N-8E12 (ABBV-8E12) an orphan drug designation for the treatment of progressive supranuclear palsy (PSP)...
UCLA Health victim of a criminal cyber attack
20 July 2015 | By Victoria White
UCLA Health was a victim of a criminal cyber attack and data on as many as 4.5 million individuals potentially may have been involved in the attack...
FDA approves Novo Nordisk’s FlexPro PenMate for people with growth hormone-related disorders
20 July 2015 | By Victoria White
The FDA has approved Novo Nordisk’s FlexPro PenMate, designed for users of Norditropin FlexPro pens who dislike needles and prefer them to be hidden...
Amgen announces positive blinatumomab Phase 2 study results in relapsed/refractory Ph+ B-Cell precursor ALL
20 July 2015 | By
Amgen has announced the top-line results of a Phase 2 trial evaluating blinatumomab in adults with relapsed or refractory Ph+ B-cell precursor ALL...
FDA QIDP designation for Motif’s iclaprim for HABP
20 July 2015 | By Victoria White
The US FDA has designated Motif Bio's iclaprim as a Qualified Infectious Diseases Product (QIDP) for hospital acquired bacterial pneumonia (HABP)...
GSK begins shipping 2015-16 US flu vaccines
17 July 2015 | By Victoria White
GSK has begun shipping Flaurix Quadrivalent (flu vaccine) doses to US healthcare providers and expects to begin shipping Flulaval Quadrivalent in August...
EC approves Evotaz for the treatment of HIV-1 infection in adults
16 July 2015 | By Victoria White
The EC has approved Evotaz tablets in combination with other antiretroviral agents for the treatment of HIV-1 infected adults...
Industry titans Biocon, PBOA, PCI Clinical Services and Pharmatech Associates join CPhI annual report for 2015
16 July 2015 | By Victoria White
CPhI Worldwide has announced the addition of four new high profile experts to the CPhI annual report, taking the total up to a record 14 panellists for 2015...
Boehringer Ingelheim welcomes inclusion of Ofev in the updated international treatment guidelines for idiopathic pulmonary fibrosis
16 July 2015 | By
Boehringer Ingelheim has welcomed new international treatment guidelines for IPF which suggest that clinicians use Ofev in patients with the disease...
Allergan receives Paragraph IV notification on Restasis
16 July 2015 | By Victoria White
Akorn Pharmaceuticals seeks approval to market a generic version of Allergan's Restasis from the US Food and Drug Administration FDA...
Immunocore secures £205 million in Europe’s largest private life sciences financing
16 July 2015 | By Victoria White
Immunocore Limited has announced the completion of a £205 million private financing round, allowing it to further accelerate its pipeline of ImmTACs...
Malaria treatment Coartem 80/480mg receives WHO prequalification
16 July 2015 | By Victoria White
Coartem 80/480mg has received WHO prequalification, making it the first high strength ACT antimalarial treatment available for public sector procurement...
Otsuka announces efficacy results for delamanid for extensively drug-resistant tuberculosis
16 July 2015 | By Victoria White
Data from a post-hoc subset analysis of Phase IIb clinical trials suggests the potential efficacy of Otsuka’s delamanid for the treatment of XDR-TB...
